These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20623701)

  • 1. The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
    Ohno T; Hasegawa C; Nakade S; Kitagawa J; Honda N; Ogawa M
    Biopharm Drug Dispos; 2010 Oct; 31(7):396-406. PubMed ID: 20623701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of an exposure-response model to aid early drug development of an oral sphingosine 1-phosphate receptor modulator.
    Rohatagi S; Zahir H; Moberly JB; Truitt KE; Inaba S; Shimozato T; Carrothers TJ
    J Clin Pharmacol; 2009 Jan; 49(1):50-62. PubMed ID: 18948412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of species difference in peripheral lymphocyte reduction effect of CS-0777, a sphingosine 1-phosphate receptor modulator, based on a pharmacokinetic/pharmacodynamic model analysis.
    Inaba SI; Goto M; Tanaka-Takanaka K; Tanaka H; Tomisato W; Yuita H; Doi-Komuro H; Inoue R; Oshima K; Kagari T; Shimozato T; Izumi T
    Biopharm Drug Dispos; 2016 Dec; 37(9):561-573. PubMed ID: 27764535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P
    Kurata H; Kusumi K; Otsuki K; Suzuki R; Kurono M; Komiya T; Hagiya H; Mizuno H; Shioya H; Ono T; Takada Y; Maeda T; Matsunaga N; Kondo T; Tominaga S; Nunoya KI; Kiyoshi H; Komeno M; Nakade S; Habashita H
    J Med Chem; 2017 Dec; 60(23):9508-9530. PubMed ID: 29120624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm.
    Krösser S; Wolna P; Fischer TZ; Boschert U; Stoltz R; Zhou M; Darpo B
    J Clin Pharmacol; 2015 Sep; 55(9):1051-60. PubMed ID: 25855155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sphingosine 1-Phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated Aplastic Anemia in a Mouse Model.
    Komiya T; Gohda M; Shioya H; Katsumata S
    J Pharmacol Exp Ther; 2021 Feb; 376(2):250-260. PubMed ID: 33257316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventive and Therapeutic Efficacy of ONO-4641, a Selective Agonist for Sphingosine 1-Phosphate Receptor 1 and 5, in Preclinical Models of Type 1 Diabetes Mellitus.
    Shioya H; Inagaki Y; Hiraizumi K; Hoshino T; Kurata H; Habashita H; Sato K; Nakade S
    Biol Pharm Bull; 2021; 44(2):188-196. PubMed ID: 33518672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of pharmacokinetic-pharmacodynamic modeling in the discovery and optimization of selective S1P(1) agonists.
    Taylor S; Gray JR; Willis R; Deeks N; Haynes A; Campbell C; Gaskin P; Leavens K; Demont E; Dowell S; Cryan J; Morse M; Patel A; Garden H; Witherington J
    Xenobiotica; 2012 Jul; 42(7):671-86. PubMed ID: 22225501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingosine 1-phosphate receptor modulator ONO-4641 stimulates CD11b
    Asakura T; Ishii M; Namkoong H; Suzuki S; Kagawa S; Yagi K; Komiya T; Hashimoto T; Okamori S; Kamata H; Tasaka S; Kihara A; Hegab AE; Hasegawa N; Betsuyaku T
    Mucosal Immunol; 2018 Nov; 11(6):1606-1620. PubMed ID: 30116000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary and vascular pharmacology of sphingosine 1-phosphate.
    Brinkmann V; Baumruker T
    Curr Opin Pharmacol; 2006 Jun; 6(3):244-50. PubMed ID: 16563863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1).
    Guo J; Watterson SH; Spergel SH; Kempson J; Langevine CM; Shen DR; Yarde M; Cvijic ME; Banas D; Liu R; Suchard SJ; Gillooly K; Taylor T; Rex-Rabe S; Shuster DJ; McIntyre KW; Cornelius G; D'Arienzo C; Marino A; Balimane P; Salter-Cid L; McKinnon M; Barrish JC; Carter PH; Pitts WJ; Xie J; Dyckman AJ
    Bioorg Med Chem Lett; 2016 May; 26(10):2470-2474. PubMed ID: 27055941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letter by Xia regarding article, "High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor".
    Xia P
    Circulation; 2007 Apr; 115(14):e393; author reply e394. PubMed ID: 17420358
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling the Effect of the Selective S1P
    Lott D; Krause A; Seemayer CA; Strasser DS; Dingemanse J; Lehr T
    Pharm Res; 2017 Mar; 34(3):599-609. PubMed ID: 28028771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
    Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off the shelf but not mass produced.
    Karliner JS
    Chem Biol; 2005 Jun; 12(6):614-5. PubMed ID: 15975506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development.
    Caruso A; Frances N; Meille C; Greiter-Wilke A; Hillebrecht A; Lavé T
    J Pharmacol Toxicol Methods; 2014; 70(1):73-85. PubMed ID: 24879942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis.
    Komiya T; Sato K; Shioya H; Inagaki Y; Hagiya H; Kozaki R; Imai M; Takada Y; Maeda T; Kurata H; Kurono M; Suzuki R; Otsuki K; Habashita H; Nakade S
    Clin Exp Immunol; 2013 Jan; 171(1):54-62. PubMed ID: 23199323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.